TY - JOUR
T1 - Is there an added value for whole body scan combined with stimulated thyroglobulin testing for follow-up of differentiated thyroid cancer patients?
AU - Giveon, Sharon
AU - Levy, Sigal
AU - Rotman-Pikieln, Pnina
AU - Rosenblum, Rachel Chava
AU - Twito, Orit
N1 - Publisher Copyright:
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2022
Y1 - 2022
N2 - Background Whole-body scan (WBS) is indicated for selected patients in the follow-up of differentiated thyroid cancer (DTC). Aim The aim of this study was to evaluate the incidence of positive WBS in patients with negative stimulated thyroglobulin (sTg), to define the clinical characteristics of this group, and the association with disease outcome. Methods DTC patients who underwent surveillance with simultaneous sTg and WBS were included. Results Two hundred seventy-two patients were included. Age at diagnosis was 46.5±15.2 years, 79% were female. Mean duration of follow-up was 11.6±6.8 years. Patients were categorised according to stimulation test results: sTg(-)/WBS(-) in 192/272 (70.6%); sTg(+) regardless of WBS results in 33/272 (12.1%); and sTg(-)/ WBS(+) in 47/272 (17.3%) subjects. sTg > 10 mg/dl was considered positive. The three groups had similar demographic and pathologic characteristics. During follow-up, additional treatment was given in 77 patients (28.3%). Twelve (4.4%) developed distant metastases; 16 patients (5.8%) died. No deaths were disease-related. There was no difference in mortality rate between categories (P = 0.182). On multivariate analysis, additional treatment was associated with male gender (P = 0.046) and positive stimulation test results, either sTg (P < 0.001) or WBS (P < 0.001). Of the 47 WBS(+)/sTg(-) patients, 7(15%) were treated due to positive WBS results, including two who underwent additional surgery. Conclusion A substantial proportion of stimulation test results were discordant. There was a significant association between WBS results and administration of additional treatment. Routine WBS had additional value for a small proportion of patients with no other evidence for disease and no indication for WBS. Nucl Med Commun 43: 663-668.
AB - Background Whole-body scan (WBS) is indicated for selected patients in the follow-up of differentiated thyroid cancer (DTC). Aim The aim of this study was to evaluate the incidence of positive WBS in patients with negative stimulated thyroglobulin (sTg), to define the clinical characteristics of this group, and the association with disease outcome. Methods DTC patients who underwent surveillance with simultaneous sTg and WBS were included. Results Two hundred seventy-two patients were included. Age at diagnosis was 46.5±15.2 years, 79% were female. Mean duration of follow-up was 11.6±6.8 years. Patients were categorised according to stimulation test results: sTg(-)/WBS(-) in 192/272 (70.6%); sTg(+) regardless of WBS results in 33/272 (12.1%); and sTg(-)/ WBS(+) in 47/272 (17.3%) subjects. sTg > 10 mg/dl was considered positive. The three groups had similar demographic and pathologic characteristics. During follow-up, additional treatment was given in 77 patients (28.3%). Twelve (4.4%) developed distant metastases; 16 patients (5.8%) died. No deaths were disease-related. There was no difference in mortality rate between categories (P = 0.182). On multivariate analysis, additional treatment was associated with male gender (P = 0.046) and positive stimulation test results, either sTg (P < 0.001) or WBS (P < 0.001). Of the 47 WBS(+)/sTg(-) patients, 7(15%) were treated due to positive WBS results, including two who underwent additional surgery. Conclusion A substantial proportion of stimulation test results were discordant. There was a significant association between WBS results and administration of additional treatment. Routine WBS had additional value for a small proportion of patients with no other evidence for disease and no indication for WBS. Nucl Med Commun 43: 663-668.
KW - differentiated thyroid cancer
KW - follow-up
KW - thyroglobulin
KW - whole-body scan
UR - http://www.scopus.com/inward/record.url?scp=85130632076&partnerID=8YFLogxK
U2 - 10.1097/MNM.0000000000001552
DO - 10.1097/MNM.0000000000001552
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 35363221
AN - SCOPUS:85130632076
SN - 0143-3636
VL - 43
SP - 663
EP - 668
JO - Nuclear Medicine Communications
JF - Nuclear Medicine Communications
ER -